Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (31-40 of 518) with videos related to

Pageof 52
Sort By:
Oncology (Williston Park, N.Y.)|September 6, 2011
Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunitiesOla Landgren, Neha Korde
Blood|December 23, 2021
Diagnosed with myeloma before age 40Ola Landgren, Dickran Kazandjian
Blood|September 1, 2012
Treating myeloma: the future is already here!Ola Landgren, Neha Korde
Blood Cancer Discovery|September 1, 2023
MRD and Plasma Cell Dynamics after CAR T-cell Therapy in MyelomaOla Landgren, Dickran Kazandjian
Leukemia & Lymphoma|May 6, 2016
Myeloma imaging: time to move on!Elisabet E Manasanch, Ola Landgren
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patientOla Landgren, Roger G Owen
Blood Cancer Discovery|December 4, 2024
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A RoadmapOla Landgren, Sean M Devlin
Seminars in Hematology|April 5, 2026
Targeted immunoPET imaging of multiple myelomaGary A Ulaner, Ola Landgren
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple MyelomaOla Landgren, S Vincent Rajkumar
Cytometry. Part B, Clinical Cytometry|September 15, 2010
Prevalence, clinical aspects, and natural history of IgM MGUSMary L McMaster, Ola Landgren
Pageof 52

Showing results (31-40 of 518) with videos related to

Sort By:
Pageof 52
Oncology (Williston Park, N.Y.)|September 6, 2011
Multiple myeloma precursor disease: current clinical and epidemiological insights and future opportunitiesOla Landgren, Neha Korde
Blood|December 23, 2021
Diagnosed with myeloma before age 40Ola Landgren, Dickran Kazandjian
Blood|September 1, 2012
Treating myeloma: the future is already here!Ola Landgren, Neha Korde
Blood Cancer Discovery|September 1, 2023
MRD and Plasma Cell Dynamics after CAR T-cell Therapy in MyelomaOla Landgren, Dickran Kazandjian
Leukemia & Lymphoma|May 6, 2016
Myeloma imaging: time to move on!Elisabet E Manasanch, Ola Landgren
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patientOla Landgren, Roger G Owen
Blood Cancer Discovery|December 4, 2024
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A RoadmapOla Landgren, Sean M Devlin
Seminars in Hematology|April 5, 2026
Targeted immunoPET imaging of multiple myelomaGary A Ulaner, Ola Landgren
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple MyelomaOla Landgren, S Vincent Rajkumar
Cytometry. Part B, Clinical Cytometry|September 15, 2010
Prevalence, clinical aspects, and natural history of IgM MGUSMary L McMaster, Ola Landgren
Pageof 52